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Abstract 
Background: Conservative surgery followed by breast and nodal irradiation is the standard loco-regional early breast 
cancer (BC) treatment for patients with four or more involved lymph nodes. However, the treatment strategy when 
fewer nodes are involved remains unclear, especially when lymphadenectomy has not been performed. Sensitive 
nodal status assessment molecular techniques as the One-Step Nucleic Acid Amplification (OSNA) assay can contrib-
ute to the definition and standardization of the treatment strategy. Therefore, the OPTIMAL study aims to demonstrate 
the feasibility of incidental irradiation of axillary nodes in patients with early-stage BC and limited involvement of the 
SLN.
Methods: BC patients who underwent conservative surgery and whose SLN total tumour load assessed with OSNA 
ranged between 250–15,000 copies/µL will be eligible. Patients will be randomized to receive irradiation on the 
breast, tumour bed, axillary and supraclavicular lymph node areas (intentional arm) or only on the breast and tumour 
bed (incidental arm). All areas, including the internal mammary chain, will be contoured. The mean, median, D5% and 
D95% doses received in all volumes will be calculated. The primary endpoint is the non-inferiority of the incidental 
irradiation of axillary nodes compared to the intentional irradiation in terms of 5-year disease free survival. Secondary 
endpoints comprise the comparison of acute and chronic toxicity and loco-regional and distant disease recurrence 
rates.
Discussion: Standardizing the treatment and diagnosis of BC patients with few nodes affected is crucial due to the 
lack of consensus. Hence, the quantitative score for the metastatic burden of SLN provided by OSNA can contribute 
by improving the discrimination of which BC patients with limited nodal involvement can benefit from incidental 
radiation as an adjuvant treatment strategy.
Trial registration: ClinicalTrial.gov, NCT02335957; https ://clini caltr ials.gov/ct2/show/NCT02 33595 7
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Background
It has been shown that breast and nodal irradiation 
reduce mortality and disease recurrence in breast cancer 
(BC) patients [1]. Therefore, there is evidence supporting 
the use of adjuvant radiotherapy after conservative sur-
gery. Since nodal irradiation increases survival rates, it 
is recommended in patients with four or more involved 
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lymph nodes (LN) [2], as well as in patients with other 
types of locally advanced tumours with LN involvement 
[3]. A randomized clinical trial carried out by the Brit-
ish Columbia Cancer Agency, showed that the 20-year 
disease-free survival (DFS) of patients subjected to the 
combination of chemotherapy and radiation was 13% 
higher than that of the patients who were treated with 
chemotherapy alone [4]. Similar results were achieved 
in the DBCG 82 b&c trial showing a difference of 10% 
in the 15-year overall survival rate between the treat-
ment combination and chemotherapy alone (39% vs. 
29%, respectively) [5]. Furthermore, a study funded by 
the Canadian Cancer Society concluded that adjuvant 
radiation treatment of limited LN-positive patients (0–3 
involved nodes) led to a decrease in disease recurrence 
[6]. However, there is no consensus on the recommenda-
tion of radiotherapy when the nodal involvement ranges 
between 1 and 3 LN [7].
Furthermore, this situation became even more unclear 
since Giuliano et  al. demonstrated no significant ben-
efit in loco-regional control with completion of axillary 
lymph node dissection (ALND) in comparison to no 
ALND in patients with 1–2 involved LN [8, 9]. On the 
other hand, AMAROS [10] and OTOASOR [11] trials 
demonstrated that nodal irradiation should be regarded 
as the recommended treatment for patients with few 
involved LN, instead of ALND. In line with their results, 
the Canadian trial NCIC-CTG MA20 [6] showed that 
local irradiation combined with regional irradiation 
improved the DFS as well as the loco-regional and dis-
tant control of the disease in high-risk patients with neg-
ative and with positive LN, mostly with 1 to 3 involved 
LN, while Poortmans et  al. [12] demonstrated that the 
irradiation of the regional nodes in patients with limited 
axillary disease results in an increase of the DFS. Darby 
et al. [13] reported that, after breast-conserving surgery, 
the application of radiotherapy to the breast reduced 
mortality and the disease recurrence by half. Finally, a 
systematic review, which included more than 20,000 
patients from 45 studies, concluded that breast irradia-
tion reduced the loco-regional relapse even in patients 
without LN involvement [14]. Later on, the meta-analysis 
conducted by Budach et al. [15, 16] concluded that addi-
tional regional radiation to the internal mammary and 
medial supraclavicular LN improved overall and disease-
free survival rates in stage I-III BC patients.
The uncertainty about the proper radiation therapy 
entails the need for a method that standardizes the choice 
of treatment and complements the limited diagnostic 
information [17–19], such as nodal involvement assess-
ment. The OSNA (One-Step Nucleic Acid Amplification) 
assay provides a quantitative value of the metastatic bur-
den of the sentinel lymph node (SLN) by measuring the 
mRNA expression of the tumour marker cytokeratin 19 
(CK19) [20]. The OSNA assay not only provides auto-
mated and complete intraoperative analyses of the SLN 
but also standardized and reliable results for SLN meta-
static status. The total tumour load (TTL), defined as the 
sum of the CK19 mRNA copies from all positive SLNs 
of the patient, entails a quantitative score that integrates 
both the metastatic burden and the number of involved 
SLN. The TTL score was proved to be an independent 
predictor factor of the axillary nodal status, where only 
14.7% of patients with TTL beneath 15.000 copies/µl 
had other positive non-SLN [21]. Recently, the PLUTTO 
study results also proved its impact on the prognosis of 
BC patients [22].
Therefore, the OPTIMAL study (OPTimizing Irra-
diation through Molecular Assessment of Lymph node) 
aims to demonstrate the non-inferiority of incidental 
irradiation of axillary nodes in comparison to inten-
tional irradiation in terms of the 5-year DFS of patients 
with early-stage BC and limited involvement of the SLN 
according to the OSNA quantitative score.
Methods/design
Study design
The OPTIMAL study is an open-label multicentre and 
international trial (NCT02335957) conducted in over 40 
sites in Spain, Portugal, and Italy. Eligible patients will be 
randomized with a 1:1 allocation ratio to receive irradia-
tion on breast, tumour bed, axillary and supraclavicular 
lymph node areas (intentional arm) or only on breast and 
tumour bed (incidental arm), as depicted in Fig. 1. Rand-
omization by blocking within centres to minimize imbal-
ance of treatments among centres will be performed 
using the online randomization software RANDI2 (www.
dkfz.de; Heidelberg University) embedded in the elec-
tronic case record form (eCRF). All patients will have to 




• Older than 18 years old
• Female invasive ductal breast cancer patients
• T1–T2 tumour stage
• Previous treatment with breast-conserving surgery 
without axillary lymphadenectomy
• OSNA assayed SLN with a TTL within the 250–
15,000 copies/µL range
• Karnofsky Performance scale Index ≥ 70%
• Written and signed Informed Consent
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Fig. 1 OPTIMAL-I study design. BC breast cancer, CK19 cytokeratin 19, mRNA messenger ribonucleic acid, SLN sentinel lymph node, TTL total tumour 
load
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Exclusion criteria
• Invasive lobular carcinoma and other histologic 
subtypes
• Bilateral breast cancer
• Male breast cancer patients
• Patients who underwent a mastectomy or ipsilat-
eral dissection of axillary LN
• Having received previous thoracic irradiation
• Systemic neoadjuvant therapy prior to surgery
• Contraindications to radiotherapy such as preg-
nancy or serious collagen disease.
• Other neoplasms and or any associated sever 
comorbidities that may interfere with the study
Endpoints
Primary endpoint
The primary endpoint is the non-inferiority of inciden-
tal irradiation of axillary nodes in contrast to inten-
tional irradiation, in terms of the 5-year DFS of patients 
diagnosed with early-stage breast cancer with limited 
involvement of the SLN treated with breast-conserva-
tive surgery without axillary lymphadenectomy.
Secondary endpoints
The secondary endpoints established were the following:
• Loco-regional tumour recurrence in the two treat-
ment arms within the 5-year follow-up period.
• Distant tumour recurrence in the two treatment 
arms within the 5-year follow-up period.
• Acute toxicity induced by either the incidental or 
intentional radiation treatment.
• Chronic toxicity induced by either the incidental or 
intentional radiation treatment.
• Total irradiation dose (Gy) received in axillary lev-




All node areas from axillary levels I-III, the supracla-
vicular fossa and the internal mammary chain must 
be contoured in all patients regardless of the assigned 
arm following the guidelines of the Radiation Therapy 
Oncology Group [23]. The Clinical Target Volumes 
(CTV) will be delimited as stated below:
• Breast The CTV includes the whole breast’s soft tis-
sues ranging from 5 mm below the skin surface to 
the deep fascia, excluding the muscle and underly-
ing ribs. The posterior margin should not extend 
beyond the deep fascia or the edges of the visible/
palpable breast in medial and lateral directions.
• Tumour bed The delineation of the tumour bed is 
only mandatory for patients who require a boost. It 
is strongly recommended to delimit the medial, lat-
eral, superior, inferior, anterior and posterior margins 
of the surgical cavity at the time of the surgery, with 
clips or gold seeds. In the absence of implanted fidu-
cial markers, the tumour bed may be localised if there 
is a well-defined seroma, considering visible changes 
in the computed tomography (CT) or by means of 
support from previous mammograms or magnetic 
resonance imaging. This volume shall be defined by 
drawing around the implanted markers and changes 
in the surrounding tissue architecture.
• Supraclavicular In the incidental arm, nodes will be 
contoured as part of the procedure whereas, in the 
control group, this will be hidden so as not to influ-
ence the dosimetric planning. The limits will be cra-
nial edge (thyroid cartilage); caudal edge (clavicle 
head); medial edge (1 cm lateral to the lateral wall of 
the trachea excluding the thyroid); lateral edge (acro-
mioclavicular joint); anterior edge (the sternocleido-
mastoid muscle and the clavicle); posterior edge (the 
trapezius muscle).
• Axilla level III In the incidental arm, nodes will be 
contoured as part of the procedure whereas, in the 
control group, this will be hidden to not influence 
the dosimetric planning. The limits will be the cra-
nial edge (5 mm cranial to the axillary vessels); caudal 
edge (1 cm caudal to the axillary vessels); medial edge 
(the ribcage); lateral edge (the res major muscle); 
anterior edge (the pectoralis major muscle); posterior 
edge (chest wall and intercostal muscles).
• Axilla level II In the incidental arm, nodes will be 
contoured as part of the procedure whereas, in the 
control group, this will be hidden to not influence 
the dosimetric planning. The limits will be the cra-
nial edge (5 mm cranial to the axillary vessels); caudal 
edge (caudal edge of pectoralis minor muscle); medial 
edge (the medial border of the pectoralis minor mus-
cle); lateral edge (the lateral border of the pectoralis 
minor muscle); anterior edge (the anterior surface of 
the pectoralis minor muscle); posterior edge (chest 
wall and intercostal muscles).
• Axilla level I In the incidental arm, nodes will be con-
toured as part of the procedure whereas, in the con-
trol group, this will be hidden to not influence the 
dosimetric planning. The limits will be the cranial 
edge (1  cm below caput humeri); caudal edge (free 
edge of pectoralis major muscle); medial edge (the 
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lateral border of the pectoralis minor muscle); lateral 
edge (the medial edge of the dorsolateral muscle); 
anterior edge (the plane defined by the anterior sur-
face of the pectoralis major and minor lateral dorsal); 
posterior edge (the anterior surface of the subscapu-
laris muscle).
• Internal mammary chain Nodes will be contoured 
in both arms and will be hidden to not influence the 
dosimetric planning. The limits will be the cranial 
edge (cranial edge of rib 1); caudal edge: (cranial edge 
of rib 5); medial edge (the edge of the sternum); lat-
eral edge (5 mm lateral of internal mammary vessels 
or 2 cm from the edge of the sternum); anterior edge 
(dorsal surface of m. pectoralis major, dorsal surface 
of the sternum); posterior edge (pleura).
• Organs at risk The delineation of ipsilateral lung 
and heart is mandatory for the calculation of dose-
volume histograms. The ipsilateral lung must be 
outlined as a single structure, and care should be 
taken not to include any airways; the CT must cover 
the entire lung volume. The heart must be outlined 
as a single structure to the extent of the pericardial 
sac; the major blood vessels (superior and inferior) 
are excluded and the superior extent may be simpli-
fied by identifying the vessels superior to the heart. 
Contralateral breast, contralateral lung, oesophagus, 
caput humeri, thyroid and spinal cord may be deline-
ated according to institutional protocols.
Enlarging all volumes by adding a 5–10 mm margin in 
all directions to create the planning treatment volume 
(PTV) is recommended.
Treatment planning
The treatment planning must be carried out on a 3D sys-
tem with tissue heterogeneity correction and matrix res-
olution of 2.5 mm. Techniques in the supine position are 
allowed and the prone position is not allowed.
• Breast Tangent beam pair arrangement to encom-
pass the whole breast is recommended, intending to 
minimize the total dose in the ipsilateral lung and 
heart. The treatment plan can be optimized with any 
dose compensation system, (virtual edges, mechani-
cal wedges, automatic wedges, field-in-field IMRT 
and steep and shoot or sliding windows IMRT). 
The treatment will be performed with photons of 6 
MV–15 MV. The isocenter will be located within the 
breast PTV in the experimental group and may be 
located outside the PTV if the single isocenter tech-
nique is being used in the control group. To minimize 
irradiated ipsilateral lung and heart volumes, collima-
tor rotation and shield with multileaf collimator is 
allowed.
• Tumour bed Photons or electrons are allowed. Mini-
tangential photon fields or single electron field (also 
mixed energies) can be utilised. The use of boluses 
can be considered if needed. Simultaneous integrated 
boost brachytherapy or intraoperative irradiation 
is also allowed if the dose contribution to the nodal 
areas can be calculated. The bolus can be used. The 
dose and fractionation choice is left at the discretion 
of the treating physician.
• Node areas In the control group, the treatment plan-
ning must be optimized to ensure that the nodal 
areas receive the prescribed dose (except for the 
internal mammary chain), minimizing the dose at the 
organs at risk. High tangent, AP/PA, conformational 
3D and IMRT techniques are allowed. In the experi-
mental group, treatment planning for nodal areas is 
not performed. The internal mammary chain will not 
be irradiated intentionally in any case.
An unplanned gap of up 3  days is acceptable. Longer 
non-planned interruptions should be compensated by 
hyperfractionation of the daily normal dose.
Dose prescription
All doses prescribed will follow the International Com-
mission on Radiation Units and Measurements guide-
lines. A minimum of 95% of the volume must receive at 
least 95% of the prescribed dose. Less than 5% of the vol-
ume may receive a dose of 105% and less than 2% should 
receive a dose of 107%, with a maximum overall dose 
of 110%. The dose in the breast must be 50.0  Gy by 25 
fractions of 2.0 Gy in 5 weeks or through hypofraction-
ated schedules as 40.05 Gy in 15 fractions of 2.67 Gy for 
3 weeks. In the tumour bed, the schedule and total dose 
are left to the centre’s criteria. In node areas, the inten-
tional irradiation to the breast and tumour bed will be 
calculated. Limiting doses for the organs at risk must be: 
(1) ipsilateral lung: V20 less than 25%; and (2) heart: V20 
less than 10% and V40 less than 5%.
Radiotherapy verification
Verification methods will be conducted in both arms. 
Treatment verification is required at the first treatment 
fraction and allowed on the three first fractions. The 
verification must be performed using electronic portal 
images of the treatment beam; either with MV or kV. 
Orthogonal images or cone-beam images can be used on 
the verification of the isocentre. Weekly control will be 
performed, and systematic daily control is also allowed.
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Follow‑up
Patients will be followed for up to 5  years after the 
intervention according to the visit schedule detailed in 
Table 1. In each visit, a physical examination and recur-
rence assessment will be performed. An image assess-
ment will be requested every year after the intervention. 
Reasons for discontinuing follow-up must be reported.
Data collection and analysis
Data collection
The study data will be recorded in an eCRF (OpenCli-
nica®, LLC). The demographic and clinical data requested 
is depicted in Table  2. Acute and chronic toxicity will 
be recorded according to the Common Terminology 
Criteria for Adverse Events v4.0 (CTCAE) [24] criteria. 
Specific follow-up outcomes will be assessed and regis-
tered during the visits scheduled as stated in Table 1.
Sample size estimation
A total of 1.400 patients must be recruited to show the 
non-inferiority of the experimental arm (incidental irra-
diation) with an 80% of statistical power when we assume 
a 5-year recurrence rate of 15% in the control arm (inten-
tional irradiation) [8], a 5% non-inferiority margin, a 
yearly dropout rate of 5%, and a fixed sample design. 
Despite the short follow-up period, the large number 
of patients to be included in the study will preserve the 
Table 1 Schedule of visits and assessments (dots) that will be performed during the 5-year follow-up period
Post‑intervention (year) 1 2 3 4 5
Post-intervention (month) 1 3 6 9 12 18 24 30 36 42 48 54 60
Acute toxicity ●
Physical exam ● ● ● ● ● ● ● ● ● ● ● ● ●
Image evaluation of local recurrence ● ● ● ● ●
Survival and disease recurrence ● ● ● ● ● ● ● ● ● ● ● ● ●
Chronic toxicity (Continuous recording)
Co-medication, (adjuvant) (Continuous recording)
Table 2 Data collected in the electronic case record form
eCRF electronic case record form, OSNA One-Step Nucleic Acid Amplification, TTL total tumour load, SLN sentinel lymph node, CTCAE Common Terminology Criteria for 
Adverse Events
a Physical examination is conducted at follow-up visits. It is also addressed at baseline and radiotherapy sessions to confirm the compliance of eligible criteria. If 
suspicious LNs are detected, the patient will discontinue the study
Panel in eCRF Data recorded
Informed consent Date
I/E criteria Yes; not
Demographic data Age at inclusion; Menstrual State
Comorbidities If yes: specify
Cancer Histology and Receptors, SLN OSNA Tumour grade; Tumour size (maximum diameter); P53 (%); Ki67 (%); Lymphovascular infiltration; Ductal Ca 
in situ; % Estrogenic receptors; % Progesterone receptors; HER2 receptor status; OSNA TTL of SLN
Previous medication (Adjuvant therapy) Drug; Start date; Stop date
Type of surgery Tumour surgery; date; Margins
Randomization Treatment randomly allocated; Randomization date
Radiotherapy intervention Patient completed the allocated treatment (If no: main reason); Start date; End date; Treatment gaps (If yes, 
reason); Dose per volume (Mean; Median; D95; D5; Volume) in the breast, tumour bed, supraclavicular 
and axillary levels I-III, and Internal mammary chain
Co-medication Drug; Start date; Stop date
Survival and disease recurrence Date of follow-up visit (If not performed, reason); Local recurrence; Regional recurrence (If yes: nodal level); 
Distant recurrence (If yes: organ); Vital status (if dead: date and cause)
Image evaluation of local recurrence Technique; Local recurrence (if yes: Maximum diameter)
Physical  examinationa Palpable breast tumour (if yes: size, skin infiltration, inflammatory carcinoma, satellite lesions); Palpable 
axillary nodes (if yes: size); Palpable supraclavicular nodes (if yes: size); Node staging
Acute and chronic toxicity CTCAE term; Grade; Start date; Stop date; Status (recovered w/o sequels; death)
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statistical significance of the survival rates and will be 
enough to evaluate differences in the toxicity rates.
Statistical analysis
Two sets of patients will be analysed: the intention-
to-treat (ITT) group, which includes all randomized 
patients, to describe the baseline clinic-pathological 
patients’ characteristics; and the per-protocol subset, 
which includes patients who finish the intervention treat-
ment as planned with all dosimetry data completed, for 
the endpoint. A descriptive analysis will be carried out 
reporting absolute and relative frequencies for all vari-
ables recorded and stratified by treatment group. Two 
analyses of the primary endpoint (disease-free survival 
rate) will be conducted. The confirmatory analyses will 
be carried out using a non-inferiority long-rank test in 
the ITT set of patients, which includes all randomized 
patients regardless of whether the treatment or follow-
up are accomplished. A secondary explanatory analysis 
will be conducted in the per-protocol subgroup, which 
will include patients who will have finished the inter-
vention treatment with all dosimetry data completed, 
by an adjusted Cox regression model using the covari-
ates: centre, age at inclusion, tumour size, hormone 
receptor status, Her2 receptor status, and OSNA results. 
With regards to the secondary endpoints: the outcomes 
of loco-regional and distant recurrence will be analysed 
using the Cox approach, this time in the ITT set. Acute 
toxicity will be analysed by a chi-squared test comparing 
frequencies in both treatment groups. Chronic toxicity 
will be analysed by using Kaplan Meier curves and com-
paring them by a standard log-rank test. Interim analy-
ses are planned when 85 events and 169 events will be 
reached.
Current status of the trial
From February 2015 to February 2020, a total of 451 
patients have been recruited (224 in the intentional arm 
and 227 in the incidental arm). Currently, acute toxic-
ity events have been reported in 319 cases. A total of 48 
chronic toxicity and 13 recurrence events have been also 
informed.
Discussion
Nowadays, early BC patients with 2 or fewer involved LN 
undergo nodal irradiation instead of lymphadenectomy 
although it is unclear whether these patients require 
local-specific treatment. This uncertainty arises from 
that current studies do not clearly describe the radiation 
volumes used as adjuvant treatment. Furthermore, some 
physicians advocate that the breast of these patients 
should be treated with high or modified tangents [25]. 
Therefore, although it is not stated as LN irradiation, 
the axillary levels I and II are being irradiated. Accord-
ingly, more than 70% of patients who had not under-
gone lymphadenectomy received LN radiation and even 
19% received unallowed supraclavicular irradiation in 
the study conducted by Giuliano et al. [26]. In line with 
previous research, a recent larger meta-analysis reported 
that expanding the radiation field to the axillary and 
supraclavicular nodes after ALND reduces locoregional 
recurrences without an improvement on the overall and 
cancer-specific survival [27]. Thus, patients’ survival 
would be improved due to the inclusion of the internal 
mammary chain in the radiation plan. Consequently, elu-
cidating the effect of node radiation by means incidental 
or intentional doses in early BC is needed.
Thus, the OPTIMAL trial was designed to outline an 
evidence-based strategy for the treatment of BC patients 
with limited nodal involvement by determining the non-
inferiority of incidental radiation of the axillary nodes 
in comparison with intentional radiation. The ESTRO 
(European Society for Radiotherapy and Oncology) 
meeting in Assisi stated the importance of further inves-
tigations on regional lymph node treatment and high-
lighted the design and expected results of the OPTIMAL, 
SENOMAC, and POSNOC studies, all of them focused 
on the treatment of patients with limited axillary disease 
[28].
Final results from the INSEMA and SOUND trials 
[29, 30], which mainly questioned the use of no-ALND 
instead of SLN biopsy procedures in early BC, may also 
contribute to better outline treatment strategies in early 
BC. Nonetheless, even though patients with limited 
LN involvement (1–3 macrometastases) are consid-
ered in these studies, whole-breast radiation therapy is 
conducted.
In the OPTIMAL trial, the SLN status and the limited 
LN involvement is determined according to the OSNA 
quantitative molecular assay [20]. At the time of the 
study design, few studies with regards to OSNA perfor-
mance had been reported. Nowadays, its contribution to 
the improvement of BC patient staging and prognosis has 
been widely reported [31]. In fact, LN assessment with 
OSNA assay and the evaluation of the TTL as a quan-
titative score of the metastatic burden of the patients is 
recommended for the management of BC patients in the 
SESPM (Spanish Society of Senology and Breast Pathol-
ogy) and the NICE (National Institute for Health and 
Care Excellence) guidelines [32–34]. This technique pro-
vides quick and standardized results at in-house diagnos-
tic laboratories, which prompts the patient’s diagnosis 
and treatment tailoring since central laboratories are not 
required for a reliable LN assessment.
In conclusion, due to the lack of consensus on the 
proper therapeutic strategy of BC patients with few 
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involved LNs standardizing the treatment and diagno-
sis is crucial. Hence, the quantitative score for meta-
static burden provided by OSNA assay can contribute by 
improving the discrimination of the BC patients with a 
limited nodal involvement who can benefit from inciden-
tal radiation as an adjuvant treatment strategy.
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